21
Rodney C Schnur: Hypoglycemic 5-substituted oxazolidine-2,4-diones. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, April 26, 1983: US04381308 (4 worldwide citation)

Hypoglycemic 5-furyl and 5-thienyl derivatives of oxazolidine-2,4-dione and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; and intermediates useful in the preparation of said compounds.


22
Rodney C Schnur: Hypoglycemic 5-pyrrolyl, indolyl and quinolyl substituted oxazolidine-2,4-diones and their use. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, January 21, 1986: US04565820 (3 worldwide citation)

Hypoglycemic 5-chromanyl, 2,3-dihydro-5-benzo[b]-furanyl, 5-pyridyl, 5-quinolyl, 5-pyrrolyl, 5-indolyl, 5-thiazolyl, 5-oxazolyl, 5-isothiazolyl and 5-isoxazolyl oxazolidine-2,4-diones and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hype ...


23
Rodney C Schnur: Hypoglycemic 5-substituted oxazolidine-2,4-diones. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, August 16, 1983: US04399296 (3 worldwide citation)

Hypoglycemic 5-phenyl and 5-naphthyl oxazolidine-2,4-diones and the pharmaceutically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyperglycemic animals therewith; and intermediates useful in the preparation of said compounds.


24
Rodney C Schnur: Spiro-quinolylhydantoins. Pfizer, Francis X Murphy, Charles J Knuth, Peter C Richardson, November 27, 1979: US04176185 (3 worldwide citation)

Novel spiro-quinolylhydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Preferred compounds include spiro[imidazolidin-4,4'-pyrano[3,2-h]quinolin]-2,5-dione and spiro[imidazolidin-4,4'-pyrano[2,3-f]q ...


25
Rodney C Schnur: Aldose reductase inhibiting 5-(2-alkoxy-3-substituted phenyl)hydantoins. Pfizer, Charles J Knuth, A E Frost, Mark Dryer, July 3, 1984: US04457939 (3 worldwide citation)

A series of 5-(2-alkoxy-3-substituted phenyl)hydantoins and pharmaceutically acceptable salts thereof useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications; intermediates therefore; and processes for preparation of said compounds.


26
Allen R Kraska, Rodney C Schnur: Aromatic amidines as antiviral agents in animals. Pfizer, Connolly and Hutz, May 24, 1977: US04025555 (3 worldwide citation)

Novel [N,N-di(higher alkyl)aminomethyl]benzamidine and substituted compounds such as [N,N-di(higher alkyl)aminomethyl]-N-(2-propyl)-benzamidine and [N,N-di(higher alkyl)aminomethyl]-N-(p-hydroxyphenyl)-benzamidine and their non-toxic acid addition salts are useful for combating viral infections in v ...


27
Rodney C Schnur: Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones. Pfizer, Peter C Richardson, J Trevor Lumb, Robert K Blackwood, March 14, 1989: US04812471 (2 worldwide citation)

Hypoglycemic 5-chromanyl, 2,3-dihydro-5-benzo[b]-furanyl, 5-pyridyl, 5-quinolyl, 5-pyrrolyl, 5-indolyl, 5-thiazolyl, 5-oxazolyl, 5-isothiazolyl and 5-isoxazolyl oxazolidine-2.4-diones and the pharmacetically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyper ...


28
Allen R Kraska, Rodney C Schnur: Aromatic amidines as antiviral agents in animals. Pfizer, Connolly and Hutz, June 27, 1978: US04097525 (2 worldwide citation)

Novel [N,N-di(higher alkyl)aminomethyl]benzamidine and substituted compounds such as [N,N-di(higher alkyl)aminomethyl]-N-(2-propyl)-benzamidine and [N,N-di(higher alkyl)aminomethyl]-N-(p-hydroxyphenyl)-benzamidine and their non-toxic acid addition salts are useful for combating viral infections in v ...


29

30
Rodney C Schnur: Spiro-oxazolidindiones. Pfizer, Francis X Murphy, Charles J Knuth, Peter C Richardson, May 12, 1981: US04267342 (2 worldwide citation)

Novel spiro-oxazolidindiones useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed.